Roumell Asset Management, run by Jim Roumell
, is reducing its exposure to Transcept Pharmaceuticals Inc (NASDAQ:TSPT
). In a recent Form 4 filing with the Securities and Exchange Commission, the fund has revealed the sale of 10,490 shares in three transactions at prices between $3.53 and $3.57. As a result, Roumell is left with 2.2 million shares.
Roumell Asset Management has been reducing its stake
for a while now. Jim Simons
, on the other hand, has been buying Transcept Pharmaceuticals Inc (NASDAQ:TSPT). His fund, Renaissance Technologies, has increased its holding by 32% during the third quarter of 2013 and currently owns 108,200 shares reportedly worth $344,000. D. E. Shaw
has also been adding to his position, with his fund, D E Shaw, reporting at the end of September ownership of 36,648 shares valued at $117,000. Cliff Asness
joined the club only recently and has initiated a position during Q3. AQR Capital Management currently holds 32,715 shares worth approximately $104,000.
Since the start of 2013, Transcept Pharmaceuticals Inc (NASDAQ:TSPT) stock has fallen 21.5% to a current share price of $3.55. With a market cap of approximately $67 million, the company does not pay a dividend and has a beta of 1.59, which makes it a fairly volatile stock. During the third quarter, Transcept registered net revenues of $382,000 and a loss of $0.25 per share.
It is worth noting that another fund invested in Transcept Pharmaceuticals, SC Fundamental Value Fund, L.P., has recently sent a letter to the board of directors
requesting a special shareholder meeting. According to the letter, shareholders are to vote on whether the company should consider continuing operation or consider selling itself/commencing liquidation. The meeting is to take place on December 19th.
Philip Hempleman, Ardsley Partners Initiate Position in Supernus Pharmaceuticals Inc (SUPN)
Carl Icahn Exercises Options and Reiterates Stake in Hologic, Inc. (HOLX)
Hedge Fund News: David Tepper, George Soros & Man Group